Table 2.
As-treated outcomes for all indications
| UMMC (%) | VAMHCS (%) | Total (%) | |
|---|---|---|---|
| 30 days | |||
| Follow-up | 7 (58) | 14 (88) | 21 (75) |
| Cure | 5 (71) | 10 (71) | 15 (71) |
| Failure | 2 (29) | 4 (29) | 6 (29) |
| Adverse eventsa | |||
| Renal | 1 (14) | 1 (7) | 2 (10) |
| Pruritus | 1 (14) | 0 (0) | 1 (5) |
aOf total patients evaluable at day 30